WuXi PharmaTech Selects Labcyte POD™ 810 Platform for High-Throughput Screening
News Dec 10, 2009
WuXi PharmaTech joins the growing number of pharmaceutical companies worldwide that have incorporated the POD system into their compound management and HTS processes.
“With this technology WuXi will remain the leader in pharmaceutical outsourcing—this demonstrates our continuous efforts to build both capabilities and capacity to help our partners to improve the success of discovery and shorten development time," commented Dr Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
“Acoustic liquid handling is clearly the method of choice in drug discovery,” said Dr. Qiang Lu, Vice President of Discovery Biology of WuXi PharmaTech. "We are very pleased to incorporate the POD 810 into our systems. It will make our drug discovery efforts significantly more productive while it reduces cost through the elimination of disposable plastic tips. We know that acoustic liquid handling will significantly improve the quality of the data we generate. We are looking forward to a continuing relationship with Labcyte."
The POD 810 plate assembler, a walk-away, out-of-the-box solution, transforms any Echo acoustic liquid handler into a Plates-On-Demand instrument. The POD system is controlled by its revolutionary Intellectual Scheduler with built-in intelligence to automatically adjust workflow to maximize productivity.
"The POD platform is uniquely positioned to advance method standardization across global sites,” said Mark Fischer-Colbrie, president and CEO of Labcyte Inc. “It eliminates the unnecessary delays associated with customized integration.”
“We are very pleased WuXi PharmaTech decided to acquire a Labcyte POD system,” said Sanger Chang, General Manager of Tekon Biotech. “Our exclusive relationship with Labcyte is further validation of our efforts to be the leading supplier of instrument systems for pharmaceutical research to the Chinese market by providing the highest level of technical support and service.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE